

# AMP europe

## THE 8<sup>TH</sup> AMPUTATION PREVENTION SYMPOSIUM (AMP) EUROPE

26-28 October 2026 | Amsterdam Marriott Hotel, The Netherlands

# PROGRAM



# Program at a Glance

## Monday 26 October 2026

- 08:00-09:30** **SESSION 1:**  
Update on CLTI (Co-Developed with CLI Global Society)
- 09:30-10:00** **REFRESHMENT BREAK**
- 10:00-12:00** **SESSION 2:**  
Wound Care and Conservative Treatment: An Essential Part of CLTI Management
- 12:00-13:00** **LUNCH BREAK**
- 13:00-14:30** **SESSION 3:**  
New Data and Late Breaking Trials
- 14:30-15:00** **REFRESHMENT BREAK**
- 15:00-17:00** **SESSION 4:**  
A Look Beyond Revascularization

## Tuesday 27 October 2026

- 08:00-09:30** **SESSION 5:**  
The Diabetic Foot- How to Optimize the Treatment Algorithm
- 09:30-10:00** **REFRESHMENT BREAK**
- 10:00-12:00** **SESSION 6:**  
Diagnostic Work-Up of the Patient with CLTI: What is Important to Know?
- 12:00-13:00** **LUNCH BREAK**
- 13:00-15:00** **SESSION 7:**  
Open Surgical & Endovascular Procedures for CLTI: Current Insights
- 15:00-15:30** **REFRESHMENT BREAK**
- 15:30-17:30** **SESSION 8:**  
The Importance of the Multi-Disciplinary Team in CLTI Treatment

## Wednesday 28 October 2026

- 08:00-09:30** **SESSION 9:**  
Complex CLTI Revascularization: Experts Share Cases & Discuss Strategies
- 09:30-10:00** **REFRESHMENT BREAK**
- 10:00-12:00** **SESSION 10:**  
Current Status of Treatment of the 'No-Option' Patient
- 12:00-13:00** **LUNCH BREAK**
- 13:00-14:30** **SESSION 11:**  
New Technologies, Techniques and Data

# Table of Contents

# AMPeurope

**THE 8<sup>TH</sup> ANNUAL AMPUTATION PREVENTION SYMPOSIUM (AMP) EUROPE**  
26-28 October 2026 | Amsterdam Marriott Hotel, The Netherlands

Welcome ..... 2

General Information ..... 3

Course Directors & Faculty ..... 4

Scientific Program ..... 6

    Monday ..... 6

    Tuesday ..... 9

    Wednesday ..... 12

Poster Presentations ..... 14

Industry Program ..... 16

Acknowledgements ..... 17

Exhibitors ..... 18

Sponsors & Exhibitors Profiles ..... 19

Adverts ..... 26

Notes



# Welcome

## Dear Colleagues & Friends,


On behalf of the Course Co-Directors, Marianne Brodmann and Thomas Zeller, I am pleased to welcome you to the 8th Amputation Prevention Symposium (AMP) Europe to be held for the fourth time in Amsterdam, The Netherlands.

AMP Europe is an expansion of the Amputation Prevention Symposium (AMP), the flagship meeting, taking place annually in August in the USA, now in its 17th year. AMP is the only meeting of its kind, focused on the prevention and treatment of chronic limb threatening ischemia (CLTI), a global public health epidemic.

The goal of the AMP Europe meeting, that started in Lugano, Switzerland in 2019, is the same as AMP in Chicago: to save limbs and save lives. AMP Europe will deliver a practical program over the next 3 days on CLTI prevalence, diagnosis, treatment (including surgical, endovascular, and medical management), and post-revascularization monitoring.

The symposium is tailored to the specific needs of the healthcare systems throughout Europe and beyond, and renowned faculty from around the world will give participants the opportunity to gain insight and perspective on CLTI advances. The format of the meeting allows for ample time for discussion after each session, and a low-threshold for peer-to-peer interaction with the expert faculty during the breaks.

I would like to thank all participants for joining us in Amsterdam and hoping you will enjoy the symposium and the city.



Jos C. van den Berg MD PhD  
AMP Europe Course Director

# General Information

## Symposium & Exhibition

The Symposium & Exhibition will take place on the 1st floor.

## Registration Hours

|                       |                |
|-----------------------|----------------|
| Monday, 26 October    | 07:00 to 17:00 |
| Tuesday, 27 October   | 07:00 to 17:00 |
| Wednesday, 28 October | 07:00 to 14:30 |

## Name Badges

Participants without badges will not be admitted to any symposium related activities.

## Language

The official language of the Symposium will be English.

## Lunches and Coffee Breaks

Coffee and lunch will be served in the Exhibition Area

## CME Credits

AMP Europe (with the Event code: LEE/2026/01689) has been granted 18.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

# Course Directors & Faculty

## Course Directors

Jos C. van den Berg, Switzerland (Course Director)

Marianne Brodmann, Austria (Co Director)

Thomas Zeller, Germany (Co-Director)

## Faculty

Vlad Alexandrescu, Belgium

Leanne Atkin, UK

Olaf Bakker, The Netherlands

Lee Bouman, The Netherlands

Marianne Brodmann, Austria

Goncalo Cabral, Portugal

Tommaso Castrucci, Italy

Edward Choke, Singapore

Vladimir Cvetic, Serbia

Gianmarco de Donato, Italy

Jean Paul de Vries, The Netherlands

Walter Dorigo, Italy

Alejandro Fabiani, Mexico

Jan Geertzen, The Netherlands

Yann Goueffic, France

Ralf Langhoff, Germany

Michael Lichtenberg, Germany

Marta Lobato, Spain

Barend Mees, The Netherlands

Bruno Migliara, Italy

Ana Mollon, Argentina

Antonio Munoa, Mexico

Ashish Patel, UK

Edgar Peters, The Netherlands

Alberto Piaggese, Italy

Mark Portou, UK

Miloš Potkonjak, Slovenia

John Rundback, USA

Tania Saez Guzman, UAE

Michiel Schreve, The Netherlands

Konstantinos Stavroulakis, Germany

Alessandro Ucci, Italy

Cagdas Unlu, The Netherlands

Jos C. van den Berg, Switzerland

Daniel van den Heuvel, The Netherlands

Jaap van Netten, The Netherlands

Bret N. Wiechmann, USA

Tim Wittig, Germany

Thomas Zeller, Germany

# SCIENTIFIC PROGRAM



# Scientific Program

## Monday, 26 October, 2026

08:00 - 09:30

### Session 1: Update on CLTI . Co-Developed with



Moderator: Jos C. van den Berg

08:00

Welcome Remarks  
**Jos C. van den Berg**, Switzerland

08:10

The CLI Global Society 2026 Update  
**John Rundback**, USA (Pre-Recorded)

08:20

The CLI Global Society EU View  
**Daniel van den Heuvel**, The Netherlands

08:30

The Perspective of a Diabetic Foot Specialist for Adequate Care in CLTI Patients  
**Alberto Piaggese**, Italy

08:40

Trombolysis in 'Acute-on-Chronic' Limb Ischemia  
**Walter Dorigo**, Italy

08:50

When will the Pandemic of CLTI, we are Expecting Flood our Hospitals?  
**Mark Portou**, UK

09:00

Transforming Outcomes: A Revascularization Program that Reduces Major Amputation Rates and Hospitalization Days in Critical Limb Ischemia  
**Ana Mollon**, Argentina

09:10

When to Stop Treatment in CLTI Patients and Switch to Palliative Care  
**Marianne Brodmann**, Austria

09:20

Panel Discussion  
**All Faculty**

09:30 - 10:00

### REFRESHMENT BREAK

10:00 - 12:00

### Session 2: Wound Care and Conservative Treatment: An Essential Part of CLTI Management

Moderator: Mark Portou

10:00

Great Flow but Poor Outcome: What Vascular Specialists Need to know About Diagnosis of Infection  
**Edgar Peters**, The Netherlands

10:10

Cost-Effectiveness of Multimodal Treatment to Prevent Foot Ulcer Recurrence  
**Jaap van Netten**, The Netherlands

10:20

Long-Term Outcomes of Wound Healing: A Single Center Experience  
**Olaf Bakker**, The Netherlands

10:30

Live in a Box: See page 16

10:50

Preliminary Outcomes of the WOUNDSinCLTI Registry  
**Thomas Zeller**, Germany

# Scientific Program

## Monday, 26 October, 2026 (cont.)

|              |                                                                                                                                                                                  |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>11:00</b> | The Role of Compression Therapy in End-Stage PAD<br><b>Leanne Atkin</b> , UK                                                                                                     |
| <b>11:10</b> | Sponsored Presentation: See page 16                                                                                                                                              |
| <b>11:20</b> | Inquests and Challenges of the Neuro-Ischemic Diabetic Foot Microangiopathy in CLTI: Why Every Presentation Should Be Considered as Unique<br><b>Vlad Alexandrescu</b> , Belgium |
| <b>11:30</b> | From Patency to Purulence: How to Treat Infection in the Diabetic Foot?<br><b>Edgar Peters</b> , The Netherlands                                                                 |
| <b>11:40</b> | Panel Discussion<br><b>All Faculty</b>                                                                                                                                           |

### 12:00 - 13:00 LUNCH BREAK

#### 13:00 - 14:30 **Session 3: New Data and Late Breaking Trials** Moderator: Marianne Brodmann

|              |                                                                                                                                                                              |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>13:00</b> | Two-Year Results of the CLTI Cohort of the BEGLORY Registry<br><b>Barend Mees</b> , The Netherlands                                                                          |
| <b>13:10</b> | BTK Laser Atherectomy: Findings from the Pathfinder Registry and the Goal of AMBITION<br><b>John Rundback</b> , USA (Pre-Recorded)                                           |
| <b>13:20</b> | The Clinical Significance of Transcutaneous CO2 Therapy: Reversing Microvascular Ischemia to Prevent Amputations<br><b>Miloš Potkonjak</b> , Slovenia                        |
| <b>13:30</b> | Atherectomy for Vessel Preparation Prior to DCB or PTA<br><b>Ralf Langhoff</b> , Germany                                                                                     |
| <b>13:40</b> | Revascularization Outcomes in Nonagenarians<br><b>Konstantinos Stravroulakis</b> , Greece                                                                                    |
| <b>13:50</b> | Two-Year Data of the THRILLER Study<br><b>Cagdas Unlu</b> , The Netherlands                                                                                                  |
| <b>14:00</b> | Long-Term Safety of Polymer Free Paclitaxel Eluting Stent for Femoropopliteal Lesions: Insights from the Nationwide FREEZE Registry<br><b>Yann Goueffic</b> , France         |
| <b>14:10</b> | Chronic Total Occlusions in Real-World PAD: Insights from a Stratified Cohort of the SUCCESS Study using a Sirolimus-Eluting Balloon<br><b>Michael Lichtenberg</b> , Germany |
| <b>14:20</b> | Panel Discussion<br><b>All Faculty</b>                                                                                                                                       |

### 14:30-15:00 REFRESHMENT BREAK

# Scientific Program

## Monday, 26 October, 2026 (cont.)

### 15:00 - 17:00 Session 4: A Look Beyond Revascularization

Moderator: Bret Wiechmann

- |              |                                                                                                                                                                                                       |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>15:00</b> | Platelet Rich Plasma, Stem Cells and Exosomes: When and How?<br><b>Antonio Munoa</b> , Mexico                                                                                                         |
| <b>15:10</b> | Use of 3D Device Guidance using Fiber Optics in Peripheral Vascular Interventions<br><b>Barend Mees</b> , The Netherlands                                                                             |
| <b>15:20</b> | Use of OCT after Bioresorbable Scaffolds: Tips and Tricks<br><b>Lee Bouwman</b> , The Netherlands                                                                                                     |
| <b>15:30</b> | IBREED RCT: A New Roadmap Technology for PAD<br><b>Yann Goueffic</b> , France                                                                                                                         |
| <b>15:40</b> | Retrograde Access: Bailout or also a Primary Strategy<br><b>Ralf Langhoff</b> , Germany                                                                                                               |
| <b>15:50</b> | Sponsored Presentation: See page 16                                                                                                                                                                   |
| <b>16:00</b> | Nutrition and Physical Activity in People at Risk of or with Dysvascular Major Lower Limb Amputation<br><b>Jan Geertzen</b> , The Netherlands                                                         |
| <b>16:10</b> | A Health Economics Analysis of a Helical 3D Geometry Stent, BMS and DES in Long, Complex SFA Lesions in the German and US Healthcare System<br><b>Michael Lichtenberg</b> , Germany                   |
| <b>16:20</b> | What is Needed after Revascularization in CLTI Patients to Prevent the Worst, Amputation?<br><b>Daniel van den Heuvel</b> , The Netherlands                                                           |
| <b>16:30</b> | Quality of Life and Clinical Outcomes following Treatment of Lower Limb Peripheral Artery Disease with a Paclitaxel-coated Balloon in a Real-World French Population<br><b>Yann Goueffic</b> , France |
| <b>16:40</b> | Cost-Effectiveness of ('off-the-shelf') DVA<br><b>Bruno Migliara</b> , Italy                                                                                                                          |
| <b>16:50</b> | Panel Discussion<br><b>All Faculty</b>                                                                                                                                                                |

# Scientific Program

## Tuesday, 27 October 2026

### 08:00 - 09:30 **Session 5: The Diabetic Foot: How to Optimize the Treatment Algorithm**

Moderator: Thomas Zeller

- |       |                                                                                                                                                                                 |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:00 | Optimizing POBA in the BTK Segment<br><b>Daniel van den Heuvel, The Netherlands</b>                                                                                             |
| 08:10 | From Dissections to Calcific Lesions: What is your Stent Algorithm<br><b>Ralf Langhoff, Germany</b>                                                                             |
| 08:20 | Why do CLTI Interventions Fail Early?<br><b>Ashish Patel, UK</b>                                                                                                                |
| 08:30 | Consensus Regarding Vessel Preparation<br><b>Konstantinos Stravroulakis, Greece</b>                                                                                             |
| 08:40 | Pre-Operative Rehabilitation in Lower Limb Patients and its Effect on Post-Operative Outcomes<br><b>Jan Geertzen, The Netherlands</b>                                           |
| 08:50 | Decoding Pain in CLTI: From Mechanisms to Tailored Therapy<br><b>Tommaso Castrucci, Italy</b>                                                                                   |
| 09:00 | Medial Artery Calcification and Small Artery Disease: A Hemodynamic Model Linking Vascular Stiffness, Wall Shear Stress and Intimal Thickening<br><b>Alessandro Ucci, Italy</b> |
| 09:10 | Is Sirolimus the Answer to Below-the-Knee Intervention?<br><b>Bret Wiechmann, USA</b>                                                                                           |
| 09:20 | Panel Discussion<br><b>All Faculty</b>                                                                                                                                          |

### 09:30 - 10:00 **REFRESHMENT BREAK**

### 10:00 - 12:00 **Session 6: Diagnostic Work-Up of the Patient with CLTI: What is Important to Know?**

Moderator: Marianne Brodmann

- |       |                                                                                                                       |
|-------|-----------------------------------------------------------------------------------------------------------------------|
| 10:00 | Index of Microcirculatory Resistance: A Future Must Have?<br><b>Lee Bouwman, The Netherlands</b>                      |
| 10:10 | Use of IVUS in the BTK Segment<br><b>Michiel Schreve, The Netherlands</b>                                             |
| 10:20 | When is Angiography not Enough in CLTI?<br><b>Ashish Patel, UK</b>                                                    |
| 10:30 | Live in a Box: See page 16                                                                                            |
| 10:50 | Impact of Calcifications on Outcome in the BTK Segment and How to Deal with it<br><b>Cagdas Unlu, The Netherlands</b> |

# Scientific Program

## Tuesday, 27 October 2026 (cont.)

- |              |                                                                                                                                |
|--------------|--------------------------------------------------------------------------------------------------------------------------------|
| <b>11:00</b> | Clinical Impact of MAC Score in CLTI Patients: A Systematic Review and Meta-Analysis<br><b>Alessandro Ucci</b> , Italy         |
| <b>11:10</b> | A Holographic Conceptualization of Flow in Diabetic Neuro-Ischemic Feet<br><b>Vlad Alexandrescu</b> , Belgium                  |
| <b>11:20</b> | CO2-Angiographic Guidance for Complex CLTI Procedures in Patients with Advanced CKD<br><b>Tim Wittig</b> , Germany             |
| <b>11:30</b> | A Brief Scrutiny of Several Bilateral Neuro-Vascular Interactions in Diabetic CLTI Limbs<br><b>Vlad Alexandrescu</b> , Belgium |
| <b>11:40</b> | Panel Discussion<br><b>All Faculty</b>                                                                                         |

## 12:00 - 13:00 LUNCH BREAK

### 13:00-15:00 Session 7: Open surgical and Endovascular procedures for CLTI: Current Insights Moderator: Marianne Brodmann

- |              |                                                                                                                                                                                                    |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>13:00</b> | Work-Up, Diagnosis and Treatment Outcomes of Peripheral (endo) Vascular Graft Infections: Results from a Cross Border Comparative Multicenter Study<br><b>Jean Paul de Vries</b> , The Netherlands |
| <b>13:10</b> | Open Surgery after Endovascular Failure<br><b>Goncalo Cabral</b> , Portugal                                                                                                                        |
| <b>13:20</b> | The Spin-Off from BEST-CLI, Lessons Learned from Subgroup Analyses<br><b>Jos C. van den Berg</b> , Switzerland                                                                                     |
| <b>13:30</b> | CLTI as Complication of Popliteal Artery Aneurysms<br><b>Walter Dorigo</b> , Italy                                                                                                                 |
| <b>13:40</b> | Long-Term Outcomes of Endovascular Repair of Popliteal Aneurysm with Specific Attention to CLTI<br><b>Jean Paul de Vries</b> , The Netherlands                                                     |
| <b>13:50</b> | Open vs. Endovascular Treatment of the CFA: 1 Year Results of the PESTO Trial<br><b>Thomas Zeller</b> , Germany                                                                                    |
| <b>14:00</b> | Open Surgical Revascularization in the Endovascular Era: When Surgery Still Matters in CLTI<br><b>Tania Saez Guzman</b> , UAE                                                                      |
| <b>14:10</b> | Vessel Prep for Endovascular Treatment of CFA: What does the Current Evidence Tell Us?<br><b>Edward Choke</b> , Malaysia (Pre-Recorded)                                                            |
| <b>14:20</b> | PSNB in CLTI Safety and Efficacy, a Prospective Study<br><b>Daniel van den Heuvel</b> , The Netherlands                                                                                            |

# Scientific Program

## Tuesday, 27 October 2026 (cont.)

**14:30**

Pedal Arch Angioplasty: Sense or Non-Sense?  
**Jos C. van den Berg**, Switzerland

**14:40**

Panel Discussion  
**All Faculty**

### **15:00 - 15:30 REFRESHMENT BREAK**

**15:30-17:30**

**Session 8: The Importance of the Multi-Disciplinary Team in CLTI Treatment**  
Moderator: **Alberto Piaggese**

**15:30**

Sustainability in Diabetic Foot Care  
**Jaap van Netten**, The Netherlands

**15:40**

Sponsored Presentation: See Page 16

**15:50**

Palliative Care as Adjunct or Alternative to Revascularization: What is the Evidence?  
**Alberto Piaggese**, Italy

**16:00**

Postprocedural Care of the CLTI Patient Still Falls Short  
**Bret Wiechmann**, USA

**16:10**

Brain Natriuretic Peptide and its Association with Survival in Patients with Dysvascular Major Lower Limb Amputation  
**Jan Geertzen**, The Netherlands

**16:20**

Co-Morbidities and the Evolution of CLTI: How to Address?  
**Alberto Piaggese**, Italy

**16:30**

When Endovascular Revascularization Fails in CLTI: When to Persist, When to Convert, When to Operate?  
**Tania Saez Guzman**, UAE

**16:40**

Holistic Assessment and Treatment of CLTI  
**Marianne Brodmann**, Austria

**16:50**

Sponsored Presentation: See Page 16

**17:00**

Nurse within the MDT: Essential or Desirable?  
**Leanne Atkin**, UK

**17:10**

Panel Discussion  
**All Faculty**

# Scientific Program

## Wednesday, 28 October 2026

**08:00-09:30**

### **Session 9: Complex CLTI Revascularization: Experts Share Cases & Discuss Strategies**

Moderator: Thomas Zeller

**08:00**

CLTI Case Study Presentation  
**Bret Wiechmann**, USA

**08:10**

All Faculty in Session

**08:20**

CLTI Case Study Presentation  
**Daniel van den Heuvel**, The Netherlands

**08:30**

All Faculty in Session

**08:40**

CLTI Case Study Presentation  
**Marta Lobato**, Spain

**08:50**

All Faculty in Session

**09:00**

CLTI Case Study Presentation  
**Cagdas Unlu**, The Netherlands

**09:10**

All Faculty in Session

**09:20**

Panel Discussion  
**All Faculty**

**09:30 - 10:00**

### **REFRESHMENT BREAK**

**10:00-12:00**

### **Session 10: Current Status of Treatment of the 'No-Option' Patient**

Moderator: Daniel van den Heuvel

**10:00**

'No-Option' - What are we Actually Talking About?  
**Alejandro Fabiani**, Mexico

**10:10**

When is DVA Technically Feasible? A Proposal for a New Scoring System  
**Alessandro Ucci**, Italy

**10:20**

Five-Year Outcomes of 'off-the-shelf' DVA, the PIPER Registry  
**Bruno Migliara**, Italy

**10:30**

Dutch Registry of purpose-built DVA  
**Michiel Schreve**, The Netherlands

**10:40**

DVA Maturation and Conversion: What is this and why?  
**John Rundback**, USA (Pre-Recorded)

# Scientific Program

## Wednesday, 28 October 2026 (cont.)

|       |                                                                                                                                   |
|-------|-----------------------------------------------------------------------------------------------------------------------------------|
| 10:50 | Hybrid Deep Venous Arterialization<br><b>Marta Lobato</b> , Spain                                                                 |
| 11:00 | DVA in Buerger's disease<br><b>Alejandro Fabiani</b> , Mexico                                                                     |
| 11:10 | Off-the-Shelf or Purpose-Built Foot Vein Arterialization: What is the Evidence?<br><b>Daniel van den Heuvel</b> , The Netherlands |
| 11:20 | Spinal Cord Stimulation in CLTI: Modulating Pain, Enhancing Perfusion<br><b>Tommaso Castrucci</b> , Italy                         |
| 11:30 | Overcoming Uncrossable BTK CTOs: My Algorithm<br><b>Edward Choke</b> , Malaysia (Pre-Recorded)                                    |
| 11:40 | Panel Discussion<br><b>All Faculty</b>                                                                                            |

### 12:00 - 13:00 LUNCH BREAK

|             |                                                                                                                                                                               |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:00-14:30 | <b>Session 11: New Technologies, Techniques and Data</b><br>Moderator: Jos C. van den Berg                                                                                    |
| 13:00       | Angiosome-Guided Ultrasound Revascularization Technique: Breaking Paradigms<br><b>Antonio Munoa</b> , Mexico                                                                  |
| 13:10       | A New Tool for Crossing CTOs<br><b>Tim Wittig</b> , Germany                                                                                                                   |
| 13:20       | The Importance and Prevention of Distal Embolization during CLTI Procedures<br><b>John Rundback</b> , USA (Pre-Recorded)                                                      |
| 13:30       | In the Era of IVL for Plaque Modification, is Atherectomy still Useful?<br><b>Bret Wiechmann</b> , USA                                                                        |
| 13:40       | Embolization during Endovascular Procedures: Prevention and Treatment<br><b>Marta Lobato</b> , Spain                                                                          |
| 13:50       | Serbian Experience with Atherectomy Devices<br><b>Vladimir Cvetic</b> , Serbia                                                                                                |
| 14:00       | Retrograde Access via Direct Puncture of the Occluded Segment in Complex Femoropopliteal Chronic Total Occlusions<br><b>Tim Wittig</b> , Germany                              |
| 14:10       | Evaluating the Impact of Distal Access on Clinical Outcomes in Lower Limb Revascularization: The Contribution of a Revascularization Program<br><b>Ana Mollon</b> , Argentina |
| 14:20       | Closing Remarks<br><b>Jos C. van den Berg</b> , Switzerland                                                                                                                   |

# Poster Presentations

1. Laser Atherectomy in Below the Knee Arteries for Chronic Limb-Threatening Ischemia:  
Early Experience with the Auryon™ Device  
**Arnaud Kerzmann**, Belgium
2. Early Recoil Following Below-The-Knee Artery Treatment with the Spur Peripheral Retrievable Scaffold System in Specific CLTI Populations: The DEEPER CHALLENGE Single-Center Prospective Study  
**Katharina Kurzmann-Guetl**, Austria
3. Spur Retrievable Scaffold Therapy (RST): DEEPER REVEAL Clinical Trial 12-Month Outcomes  
**S. Jay Mathews**, USA



# INDUSTRY PROGRAM



# Industry Program

## Monday, 26 October 2026

**10:30** Live in a Box: Sponsored by   
BTK Revascularization with Oscar: Cases, Insights and Lessons Learned  
**Gianmarco de Donato**, Italy

---

**11:10** From Clinical Data to Daily Practice: Managing CLTI with Shockwave IVL  
(Sponsored by )  
**Mark Portou**, UK

---

**15:50** Redefining Calcium Treatment: The Shockwave IVL Mechanism of Action  
(Sponsored by )  
**Ashish Patel**, UK

## Tuesday, 27 October 2026

**10:30** Live in a Box: Sponsored by   
Beyond Angiography: Understanding Vessel Response with the Novel Spur  
Retrievable Scaffold  
**Bruno Migliara**, Italy

---

**15:40** The Prosonic System : The Intravascular Ultrasonic Technology to Cross Complex Lesions  
and CTO's: Case Experiences in the FREEFLOW Pivotal Study Data (Sponsored by )  
**Marianne Brodman**, Austria

---

**16:50** 5F iliac Stenting using the QBX Platform: Results of a Single Center Registry and Tips and  
Tricks on how to Optimize Results (Sponsored by )  
**Jos C. van den Berg**, Switzerland

# Acknowledgements

We would like to thank our sponsors & exhibitors for their support of AMP Europe.

## Gold Sponsor

**Medtronic**  
Engineering the extraordinary

## Silver Sponsors

**Johnson & Johnson**  
MedTech

 **REFLOW MEDICAL**  
THE PULSE OF MEDICAL INGENUITY

**Teleflex**  
Empowering the future of healthcare

**Verano**  
MEDICAL

## Bronze Sponsors

 **angiodynamics**

**Boston Scientific**  
Advancing science for life™

**COOK**  
MEDICAL

 **Cordis**

 **PVRmed**  
Peripheral Vascular Rehabilitation

**Q<sup>3</sup> Medical**  
GROUP

## Educational Grants

**INNOVATION** SWISS BRANCH  
HEALTHTECHNOLOGY SOLUTIONS CONTO, SUSTAINABLE & CHANGING

**Medtronic**  
Engineering the extraordinary

**micro medical**  
solutions

## Other Sponsors

 **Concept Medical**

 **plusmedica**

 **VASCULAR**

# Exhibitors

We kindly request participants to visit the exhibition area.



# Sponsors & Exhibitors Profiles

## ANGIODYNAMICS

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life. The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs.



## BOSTON SCIENTIFIC

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we offer the broadest portfolio of peripheral intervention solutions, supporting physicians in delivering efficient, evidence-based care across all levels of vascular complexity.

Our Modern Endovascular Interventions (Modern EVI) approach, built around SEE More, PREP Smarter, and TREAT Better, is redefining procedural standards and helping more patients benefit from minimally invasive therapies. Through our commitment to clinical research, medical education, and innovation, we empower physicians to advance endovascular care with the industry's most comprehensive Modern Endovascular Portfolio.



## CONCEPT MEDICAL

Concept Medical is a global medical technology company focused on developing innovative drug-delivery platforms and interventional solutions for coronary and peripheral vascular disease. The company combines proprietary coating technologies, device engineering and a growing body of clinical evidence to address unmet needs in vascular intervention. Concept Medical has built a global presence across more than 80 countries. Its portfolio is centered on drug-coated balloon and drug-eluting technologies designed for coronary and peripheral applications.



# Sponsors & Exhibitors Profiles

## COOK MEDICAL

Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: our patients, our employees and our communities. For the latest news, follow us on social media.



## CORDIS

From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for nearly 70 years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions—powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education, Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.



## CLI GLOBAL SOCIETY

The Critical Limb Ischemia (CLI) Global Society's mission is to improve the quality of life by preventing amputations and death due to CLI. The Society collaborates with a coalition of like-minded organizations that share an interest in CLI to address treatment, outcomes, coding, and reimbursement to globally improve care and prevent amputations for patients with CLI.



## INNOVA HTS SA

INNOVA HTS SA is a national distributor of medical devices focused on Cardiovascular field.

Its mission is to position itself as the ideal Sales & Marketing Incubator for start-up companies with innovative products, while also serving as a strategic partner for established companies with high-volume products that wish to leverage the experience and expertise of its founders.

INNOVA HTS SA is a strategic partner able to work closely with manufacturing companies, thanks to the in-depth knowledge of the market and its key stakeholders. Innova HTS SA means guarantee of quality, reliability and professionalism.



# Sponsors & Exhibitors Profiles

## PLUS MEDICA

Plus Medica is a MedTech company that develops and markets innovative solutions for the treatment of venous and peripheral arterial vascular diseases. Working closely with experienced partners, plus medica explores forward-thinking technologies and continuously researches new treatment methods. Key priorities include patient safety, usability, and therapeutic efficiency. With several specialized units, the plus medica group combines expertise with a strong commitment to innovation. Plus Medica sees itself not only as a distributor, but as a driving force in vascular medicine. Across all areas, quality takes precedence over quantity, and innovation is consistently valued more than tradition.



## PVR

PVR Med is a medical technology company dedicated to restoring microvascular perfusion in Chronic Limb-Threatening Ischemia (CLTI) and diabetic foot disease. The company's proprietary, non-invasive microvascular therapeutic platform targets tissue-level perfusion deficits where macrovascular interventions alone fall short. Backed by randomized sham-controlled and multicenter clinical data, PVR Med restores microcirculatory function, accelerates the healing of diabetic foot ulcers, and improves diabetic neuropathy. Positioned as an essential adjunct to revascularization and "no-option" limb salvage, PVR Med is advancing a new paradigm in microvascular therapeutics.



## Q3 MEDICAL GROUP

At Q3 Medical Group, our vision of "Creating Value by Helping People" drives everything we do. We are revolutionizing healthcare through cutting-edge micro-invasive technologies and advanced biodegradable solutions. Our mission is to develop and commercialize innovative, minimally invasive technologies that significantly enhance patient outcomes by reducing complications, lowering costs, and minimizing the need for removal procedures. With a focus on patient-centered care, hospital economics and sustainability, we're setting new standards in healthcare with our state-of-the-art solutions.



## R3 VASCULAR

R3 Vascular is a privately held, early-stage medical device company (Mountain View, CA, USA) that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of PAD below the knee. The R3 Vascular platform is designed to deliver the 'stent-like' support of a scaffold along with the anti-inflammatory result of sirolimus, but 'disappearing' over time as the vessel heals. At a 98-micron strut thickness across all its range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in a percutaneous setting



# Sponsors & Exhibitors Profiles

## REFLOW MEDICAL

Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company's portfolio includes coronary and peripheral microcatheters, crossing catheters, and a revolutionary device enabling Retrievable Scaffold Therapy (RST). The coronary CoraCatheters line are FDA approved. The peripheral product line includes Wingman™, Spex®, Spex LP and Spur® and have FDA clearance and CE Mark registration. Reflow Medical is headquartered in San Clemente, California.



## JOHNSON & JOHNSON MEDTECH

As part of Johnson & Johnson MedTech, innovation is in our DNA. We never settle for the status quo and are constantly pioneering ways to address unmet clinical needs with low-risk treatment options for patient populations suffering from cardiovascular disease. From Intravascular Lithotripsy (Shockwave IVL) to Coronary Sinus Reduction and beyond, our circulatory restoration solutions transform lives around the world.

Johnson & Johnson  
MedTech

## STENTiT

STENTiT is a Dutch medical device company developing the Resorbable Fibrillated Scaffold (RFS), a novel vascular implant for patients with chronic limb-threatening ischemia (CLTI), designed to provide temporary mechanical support while promoting the formation of new vascular tissue. The scaffold is designed to gradually resorb, leaving no permanent implant behind.

STENTiT

# Sponsors & Exhibitors Profiles

## TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ - trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit [teleflex.com](http://teleflex.com).



## VERSONO

Versono Medical is advancing intravascular ultrasonic technology to address a critical challenge in endovascular intervention: crossing complex peripheral chronic total occlusions (CTOs).

Built on proprietary FastWire® Technology, its investigational ProSonic™ System combines axial and radial ultrasonic energy and is designed to support intraluminal CTO crossing as a pathway to follow-on therapies.

"Crossing Comes First" underpins Versono's approach, with development focused on the challenges physicians face when navigating complex occlusive disease. The system remains investigational, is not CE marked and is not available for sale or commercial use.



# **AMP**europe

THE AMPUTATION PREVENTION SYMPOSIUM

## **SEE YOU IN 2027**

Together we will continue to  
**SAVE LIMBS AND LIVES**

# ADVERTS



# AURYON

# ENGINEERED TO EMPOWER YOUR EXPERTISE



## ADAPTABLE

Treats all levels of calcification<sup>1,4</sup>

- Indicated for in-stent restenosis (ISR) and can be used to treat patients with acute limb ischemia (ALI)
- Treats infrainguinal lesions both above and below the knee (including below the ankle)
- Nonreactive to contrast media for simultaneous ablation and observation of fluoroscopy image



## PRECISE

Protective of the vessel wall<sup>1,3,5,6</sup>

- Performs targeted biological reactions to address risk of perforations
- Wavelength produces a photon energy that's hard on calcium and soft on vessel walls
- Vaporizes lesions without thermal ablation



## EFFICIENT

Performance designed for your lab<sup>1,3</sup>

- Defines a new standard in efficacy and safety outcomes
- Has the potential to debulk in fewer passes
- Small footprint, unparalleled portability, and simple storage
- Easy installation, using a 110V and 220V outlet, touchscreen, and low acoustic noise

### Risk Information:

**Caution:** Federal (USA) law restricts the use of the system by or on the order of a physician.

Refer to Directions for Use and/or User Manual provided with the product for complete Instructions, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product.

### US Indications for Use:

The Auryon Atherectomy System and Auryon Atherectomy Catheters with aspiration are indicated for use as atherectomy devices for arterial stenoses, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and stented infra-inguinal arteries.

The Auryon Atherectomy System and Auryon Atherectomy Catheters without aspiration are indicated for use in the treatment, including atherectomy, of infra-inguinal stenoses and occlusions.

### CE Mark Indication for Use:

The Auryon Atherectomy System used together with Auryon Atherectomy Catheters with aspiration are indicated for use as atherectomy devices for arterial stenoses and occlusions, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and stented infra-inguinal arteries.

The Auryon Atherectomy System used together with the Auryon Atherectomy Catheters without aspiration are indicated for use as atherectomy devices for arterial stenoses and occlusions, including in-stent restenosis (ISR), in native and stented infra-inguinal arteries. The Auryon System is not available in all regions. Please contact your AngioDynamics representative for availability.



AngioDynamics, the AngioDynamics logo, Auryon, and the Auryon logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. © 2026 AngioDynamics, Inc. GL/PA/AD/4754 Rev 01/10/2026


# Are all stents performing the same?

New **meta-analysis**  
comparing  
femoropopliteal  
stents

TREAT better.



**ELUVIA™**  
Drug-Eluting Stent



**141**  
studies

**35,890+**  
patients

**4**  
stent types

# 1 clear performer

Scan to read the full article

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at [www.IFU-BSCI.com](http://www.IFU-BSCI.com). Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.  
© 2026 Boston Scientific Corporation or its affiliates. All rights reserved. PI-2458207-AA C€ 0344




# Nothing beats Zilver® PTX®

## Real-world REALDES study shows lower rate of in-stent occlusions with Zilver PTX than Eluvia®.1

No difference in primary patency or CD-TLR between Zilver PTX and Eluvia, despite longer lesions treated in the Zilver PTX arm

### Lower rate of in-stent occlusions for Zilver PTX



**Zilver PTX**  
96 limbs  
(86 patients)

**Eluvia**  
104 limbs  
(98 patients)

**Mean lesion length**  
 $p=0.0295$

185.7  
±  
92 mm

160.0  
±  
98.5 mm

**Primary patency**  
 $p=0.74$

70.0%

65.2%

**Freedom from CD-TLR**  
 $p=0.27$

79.4%

76.3%

Primary patency defined as a peak systolic velocity ratio of  $\leq 2.4$ , without clinically driven target lesion revascularisation (CD-TLR) or stenosis  $\geq 50\%$  based on angiographic findings.

Eluvia is a registered trademark of Boston Scientific Scimed, Inc.

Please follow the step-by-step instructions carefully, including the risk, technical information, Device Name and intended use provided in the IFU at [cookmedical.eu](http://cookmedical.eu). Note that some products or part numbers may not be available in all markets; consult your Cook representative for details. All included products meet the EU requirements for CE mark or an exemption.

1. Shibata T, Iba Y, Shingaki M, et al. Comparative analysis of three year results of two paclitaxel related stents for the management of femoropopliteal disease in a real world setting. *Eur J Vasc Endovasc Surg.* 2025;51078-5884(25)00238-2. doi: 10.1016/j.ejvs.2025.03.010. Online ahead of print.

2. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. *J Am Coll Cardiol.* 2012;59:16-23.

**Zilver® PTX®**  
DRUG-ELUTING PERIPHERAL STENT

► READ MORE.



See the 3-year  
REALDES results.






# SELUTION SLR™

PTA DRUG-ELUTING BALLOON

**3 YEAR FREEDOM FROM CD-TLR**

**93.8%<sup>1</sup>**

**A SAFE, DURABLE, AND EFFECTIVE  
ALTERNATIVE TO PACLITAXEL DCBS  
FOR FEMOROPOPLITEAL DISEASE<sup>1,2</sup>**



1. Soga, Y, Iida, O, Saito, S. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting Balloon. J Am Coll Cardiol Interv. 2025 Nov, 18 (21) 2629-2637.

2. M. Lichtenberg, "First report of the 12-month data from the SUCCESS PTA study: Sirolimus DEB in real-world patients with peripheral arterial disease", Oral Presentation at Charing Cross Conference 2025

For Healthcare Professionals Only.

Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. SELUTION SLR Drug-Eluting Balloon, CE 0344, is manufactured by MedAlliance, LLC and its affiliates. SELUTION SLR is a trademark of M.A. Med Alliance SA. MedAlliance, LLC and M.A. Med Alliance SA are Cordis companies. CORDIS and Cordis LOGO are trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners.




PERIPHERAL RETRIEVABLE SCAFFOLD SYSTEM




REFLOW MEDICAL®  
THE PULSE OF MEDICAL INGENUITY

# SEE SPUR IN ACTION



**Join Bruno Migliara, MD, for a recorded  
live case exploring BTK vessel response  
with Spur Retrievable Scaffold Therapy**

**Tuesday, October 27 | 10:30 AM**



Scan to learn more about Spur

©2026 Reflow Medical, Inc. All rights reserved. Reflow Medical, Spur, and The Pulse of Medical Ingenuity are registered trademarks or trademarks of Reflow Medical, Inc.

[www.reflowmedical.com](http://www.reflowmedical.com) | [info@reflowmedical.com](mailto:info@reflowmedical.com)

CE  
2797

Shockwave Peripheral IVL

# Establishing a new benchmark for patients with CLTI

Results from the DISRUPT BTK II study show that in a majority of patients with CLTI, Shockwave™ IVL plays a critical role in laying the foundation for successful wound healing through safe and effective revascularization.



9/10

patients were  
free from major  
amputation



2/3

patients achieved  
wound healing  
or improvement\*



Explore Shockwave IVL  
for calcified BTK lesions

\*Mean wound follow up time: 157 days

Armstrong E, One-Year Outcomes From the Disrupt PAD BTK II Study: Treatment of Patients With Calcified Below-the-Knee Lesions With a Peripheral Intravascular Lithotripsy System, VIVA 2025

Prior to use, please reference the Instructions for Use for the information on indications, contraindications, warnings, precautions, and adverse events. [www.shockwavemedical.com/IFU](http://www.shockwavemedical.com/IFU) Product availability may vary by country. ©2026 Shockwave Medical Inc. All rights reserved. SPL 82024 Rev. C.

Johnson & Johnson  
MedTech

## Organized by:



### **HMP Global**

70 E. Swedesford Road, Suite 100  
Malvern, PA 19355, USA  
Phone: +1 610 560 0500  
Fax: +1 610 560 0502



### **GTGL Global Events**

Rue des Poissonniers 13 1000  
Brussels, Belgium  
Phone: +32 (0)2 786 1968  
Email: [gail@gtgevents.com](mailto:gail@gtgevents.com)